ArticleMedicine2025
Aspartame and cardiovascular disease: Unraveling potential molecular mechanisms through integrative network toxicology, molecular docking, and dynamics simulation.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspartame, a widely used artificial sweetener, has raised growing concerns regarding its potential cardiovascular toxicity. While regulatory agencies deem it safe within established limits, emerging evidence suggests possible adverse effects on vascular and inflammatory systems. This study aimed to investigate the potential molecular mechanisms by which aspartame may contribute to cardiovascular disease, utilizing a network toxicology approach combined with molecular docking and dynamics simulation. Potential aspartame targets were predicted using ProTox 3.0 and ADMETlab 2.0 platforms, alongside ChEMBL, STITCH, and Swiss Target Prediction databases. Cardiovascular-related targets were identified via GeneCards, Online Mendelian Inheritance in Man, and the Therapeutic Target Database. Overlapping genes were analyzed through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment. A protein-protein interaction network was constructed and analyzed for hub gene identification. Molecular docking and 100 ns molecular dynamics simulations were performed to validate binding stability between aspartame and key targets. Fifty-three overlapping genes were identified between aspartame and cardiovascular disease-related targets. Three hub proteins - interleukin-1β, caspase-3, and SRC - were revealed as potential regulators of aspartame-induced cardiovascular effects. Aspartame demonstrated stable binding to these proteins, particularly CASP3. Functional enrichment highlighted the AGE-RAGE, NF-κB, and PI3K-Akt signaling pathways as key mediators. Our findings suggest that aspartame may influence cardiovascular health through coordinated modulation of inflammatory and apoptotic pathways. These results provide a molecular framework for further experimental validation and risk stratification in sensitive populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.